Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267083 | 0.83 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL27887816 | 0.80 | TSHR (0.37) | TSHR | |
| SCHEMBL31216724 | 0.80 | ALDH1A1 (0.39) | USP2ALDH1A1LMNATSHR | |
| SCHEMBL2057369 | 0.79 | ALDH1A1 (0.52) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL9620356 | 0.78 | ALDH1A1 (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL9620606 | 0.78 | ALDH1A1 (0.38) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2058106 | 0.74 | ALDH1A1 (0.56) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2057810 | 0.72 | TSHR (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2057711 | 0.72 | TSHR (0.54) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4305884 | 0.72 | ALDH1A1 (0.50) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472342-A1 | SCREENING FOR CHEMOTHERAPY RESISTANCE IN HUMAN HAPLOID CELLS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221225-A9 | SCREENING FOR CHEMOTHERAPY RESISTANCE IN HUMAN HAPLOID CELLS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-03-21 | — | — | WO | disclosed |
| WO-2017221225-A1 | SCREENING FOR CHEMOTHERAPY RESISTANCE IN HUMAN HAPLOID CELLS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-12-28 | — | — | WO | disclosed |
| WO-2016038609-A1 | ANTI-HER3 ANTIBODIES AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-03-17 | — | — | WO | disclosed |
| WO-2015037009-A1 | ISOLATED PROTEINS CAPABLE OF BINDING PLEXIN-A4 AND METHODS OF PRODUCING AND USING SAME | PLEXICURE LTD. (IL) | 2015-03-19 | — | — | WO | disclosed |
| WO-2007078615-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER | CAVIT SCIENCES, INC (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1611153-A2 | ANTITUMOR EFFECT OF MUTANT BIK | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089981-A2 | ANTITUMOR EFFECT OF MUTANT BIK | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-10-21 | — | — | WO | disclosed |
| EP-1425002-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENTS IN THE TREATMENT OF CANCER | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022258-A1 | ARYLOXYPROPYLAMINES AS CHEMOSENSITIZING AGENT IN THE TREATMENT OF CANCER | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-03-20 | — | — | WO | disclosed |
| US-6136835-A | VIRICIDES USING BIS/TRIAZOLE PROPANOL DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-24 | — | — | US | disclosed |
| US-5776925-A | TEXAPHYRINS | PHARMACYCLICS, INC. (US) | 1998-07-07 | — | — | US | disclosed |